These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8935603)

  • 41. Systemic vasculitis and the gut.
    Hatemi I; Hatemi G; Çelik AF
    Curr Opin Rheumatol; 2017 Jan; 29(1):33-38. PubMed ID: 27684357
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Two cases of classical polyarteritis nodosa associated with a low titre of MPO-ANCA].
    Bohgaki T; Mukai M; Notoya A; Kohno M
    Ryumachi; 2000 Feb; 40(1):9-15. PubMed ID: 10783660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vasculitis of the central and peripheral nervous system mimicking brain death.
    Vivekananda U; Hirsch NP; Kullmann DM; Alvarez D; Phadke R; Howard RS
    Clin Neurol Neurosurg; 2012 May; 114(4):399-401. PubMed ID: 22134104
    [No Abstract]   [Full Text] [Related]  

  • 44. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
    N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Dementia due to cerebral vasculitis].
    Kitagawa Y
    Nihon Rinsho; 2004 Jan; 62 Suppl():435-40. PubMed ID: 15011401
    [No Abstract]   [Full Text] [Related]  

  • 46. Isolated vasculitis of the urinary bladder: a note on diagnosis and prognosis.
    Fall M; Höper L; Kåbjörn-Gustafsson C; Trysberg E
    Scand J Urol; 2018 Jun; 52(3):230-231. PubMed ID: 29514535
    [No Abstract]   [Full Text] [Related]  

  • 47. Consensus therapeutic regimens for ANCA-associated systemic vasculitis. The European Community Systemic Vasculitis Study Group.
    Rasmussen N
    Lancet; 1997 Apr; 349(9057):1029-30. PubMed ID: 9100656
    [No Abstract]   [Full Text] [Related]  

  • 48. A case report of steroid-resistant antineutrophil cytoplasmic antibody-related vasculitis successfully treated by mizoribine in a hemodialysis patient.
    Tokunaga M; Tamura M; Kabashima N; Serino R; Shibata T; Matsumoto M; Miyamoto T; Miyazaki M; Furuno Y; Fujimatsu S; Muta T; Takeuchi M; Abe H; Okazaki M; Otsuji Y
    Ther Apher Dial; 2009 Feb; 13(1):77-9. PubMed ID: 19379174
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current attitudes to the therapy of vasculitis.
    Jayne D
    Kidney Blood Press Res; 2003; 26(4):231-9. PubMed ID: 14504423
    [No Abstract]   [Full Text] [Related]  

  • 50. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
    Ozaki S
    Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Scleroderma associated with ANCA-associated vasculitis.
    Rho YH; Choi SJ; Lee YH; Ji JD; Song GG
    Rheumatol Int; 2006 Mar; 26(5):465-8. PubMed ID: 16012875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
    Sanders JS; Slot MC; Stegeman CA
    N Engl J Med; 2003 Nov; 349(21):2072-3; author reply 2072-3. PubMed ID: 14627795
    [No Abstract]   [Full Text] [Related]  

  • 53. Cerebral Amyloid Angiopathy with Angiitis: Emerging Options for Treatment.
    Cagle K; Berg A; Freeman J
    S D Med; 2015 Jul; 68(7):293-6. PubMed ID: 26267928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. When should patients with ANCA-associated vasculitis be switched from induction to maintenance therapy?
    Flossmann O; de Groot K
    Nat Clin Pract Nephrol; 2007 May; 3(5):236-7. PubMed ID: 17457358
    [No Abstract]   [Full Text] [Related]  

  • 55. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
    Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
    Rheumatology (Oxford); 2006 Jun; 45(6):724-9. PubMed ID: 16399845
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Effects of Plasma Exchange on Severe Vasculitis with Diffuse Alveolar Hemorrhage.
    Goto K; Nakai K; Fujii H; Nishi S
    Intern Med; 2017; 56(1):55-59. PubMed ID: 28050000
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Vasculitis and diabetes insipidus, reversible by administration of cyclophosphamide].
    Mallet H; Dupond JL
    Presse Med; 1995 Nov; 24(36):1709. PubMed ID: 8545406
    [No Abstract]   [Full Text] [Related]  

  • 58. [Anti-cytoplasm antibodies to polynuclear neutrophils: specificity in renal vasculitis].
    Soler C; Dupré-Goudable C; Rey JP; Modesto A; Oksman F; Suc JM
    Ann Biol Clin (Paris); 1993; 51(2):133-9. PubMed ID: 8214812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
    Lapraik C; Watts R; Bacon P; Carruthers D; Chakravarty K; D'Cruz D; Guillevin L; Harper L; Jayne D; Luqmani R; Mooney J; Scott D;
    Rheumatology (Oxford); 2007 Oct; 46(10):1615-6. PubMed ID: 17804455
    [No Abstract]   [Full Text] [Related]  

  • 60. Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.
    Padhan P
    Ann Intern Med; 2010 Jan; 152(1):64; author reply 65. PubMed ID: 20048279
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.